Fintel reports that on December 2, 2024, Morgan Stanley upgraded their outlook for Tandem Diabetes Care (NasdaqGM:TNDM) from ...

Investment analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of Tandem Diabetes Care in ...

Leerink Partners analyst Mike Kratky maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on November 25 and set a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bullish Analyst Says RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 ...

Modular Medical (Nasdaq:MODD) announced recently that it priced an underwritten public offering worth proceeds of around $8.2 ...

Some of the key market players operating in the implantable infusion pump market include Medtronic, Flowonix Medical, Intera Oncology, Tandem Diabetes Care, United Therapeutics, ICU Medical, Johnson & ...

AM Best has maintained its market segment outlook for the U.S. life/annuity insurance segment at stable, supported by strong capitalization across the industry, robust top-line growth in core lines of ...